%0 Journal Article
%T Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.
%A Leucker TM
%A Osburn WO
%A Reventun P
%A Smith K
%A Claggett B
%A Kirwan BA
%A de Brouwer S
%A Williams MS
%A Gerstenblith G
%A Hager DN
%A Streiff MB
%A Solomon SD
%A Lowenstein CJ
%J JACC Basic Transl Sci
%V 6
%N 12
%D Dec 2021
%M 34904132
%F 9.531
%R 10.1016/j.jacbts.2021.09.013
%X COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients with moderate COVID-19 were randomly assigned to receive either placebo or crizanlizumab, a P-selectin inhibitor, in a double-blind fashion. Crizanlizumab reduced P-selectin levels by 89%. Crizanlizumab increased D-dimer levels by 77% and decreased prothrombin fragment. There were no significant differences between crizanlizumab and placebo for clinical endpoints. Crizanlizumab was well tolerated. Crizanlizumab may induce thrombolysis in the setting of COVID-19. (Crizanlizumab for Treating COVID-19 Vasculopathy [CRITICAL]; NCT04435184).